TickerHumSide-by-side comparison
Bristol-Myers Squibb vs Moderna
As of Nov 11, 2026, P/S is 2.6x for Bristol-Myers Squibb vs 39.9x for Moderna; revenue growth is 4.2% for Bristol-Myers Squibb vs 13.1% for Moderna; net margin is 18.5% for Bristol-Myers Squibb vs -110.5% for Moderna; debt/equity is 1.79 for Bristol-Myers Squibb vs 0.09 for Moderna.
What stands out
- Moderna carries less debt relative to equity: 0.09 vs 1.79 for Bristol-Myers Squibb.
- Bristol-Myers Squibb scores higher on TickerHum's ratings: 69/100 vs 47/100 for Moderna.
Key metrics
| Metric | BMY | MRNA |
|---|---|---|
| Price | $62.91 | $248.69 |
| Market cap | $128.59B | $100.63B |
| P/E | 13.9x (#1) | — |
| P/S | 2.6x (#1) | 39.9x (#2) |
| Revenue growth | 4.2% (#2) | 13.1% (#1) |
| Operating margin | — | -116.0% (#1) |
| Net margin | 18.5% (#1) | -110.5% (#2) |
| Debt / equity | 1.79 (#2) | 0.09 (#1) |
| 1-year return | +28.2% (#1) | — |
| Research score | 69/100 (#1) | 47/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Moderna, Inc. (MRNA) — Biotechnology